Patent application filed for immunomodulatory compounds and use thereof for the treatment and/or prevention of infectious diseases.
31 August 2020
Patent application filed for three kinase inhibitors and use thereof to mediate the loss of malignant character of tumor cells.
8 June 2020
AC BioScience presents at the International Cancer Cluster Showcase (ICCS), a satellite event to BIO 2020.
25 May 2020
AC BioScience raises CHF 1 million in second seed funding.
27 March 2020
Patent application filed for a combination of flavonoids and S1P lyase inhibitors for the treatment of lung inflammation.
15 March 2020
Patent application filed for RGD-peptide and use thereof for inhibiting RGD-binding integrins and for cancer treatment.
13 March 2020
Innosuisse approves research grant for a collaborative project with the University of Lausanne on a new therapy targeting pathogen-dependent immune subversion mechanisms for infectious diseases treatment.
7 January 2020
Collaboration Agreement signed with the Institut Gustave Roussy (IGR) for radiation therapy in combination with S1P metabolism modulators, and ACB1801 with anti PD-1 treatment, respectively.
26 August 2019
Cooperation Agreement signed with the Luxembourg Institute of Health (LIH) to determine the efficacy of combination approaches of ACB1801 with anti-PD-1 drugs.
21 August 2019
Patent application filed for various metabolites of S1P lyase inhibitors for the treatment of infectious diseases and cancer.
06 May 2019
AC BioScience presents at the Swiss Biotech Day 2019.
25 March 2019
Patent application filed for a Beta-carboline derivative (ACB1801) for the non-toxic and immunological treatment of cancer.
08 March 2019
AC BioScience raises CHF 1 million in seed funding.
AC BioScience acquires a majority share in AC BioTech SAS in Paris.
29 May 2018
Collaborative Research Agreement signed with the University of British Columbia, Vancouver, on S1P lyase inhibitors.
26 April 2018
Innosuisse approves research grant for a collaborative project with the University of Geneva on tumor vascular normalizers (S1P).
Collaborative Research Agreement signed with the Institut Curie, Paris; commencement of a pharmacological PDX study of NSCLC for CAP6.
24 August 2017
Conversion to a private limited stock company (Ltd.) with an increased capital of CHF 500,000; acquisition of a patent for a Peptide having the sequence SEQ.1 for use as a medicament, in particular for the treatment of cancer.
17 August 2017
Patent application filed for the enhancement of chemotherapy efficiency by Sphingosine-1-phosphate (S1P).
31 March 2017
AC BioScience established as a Limited Liability Company (LLC) at the EPFL Innovation Park.